Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Mangiacavalli, Silvia; Cocito, Federica; Ferretti, Virginia Valeria; Cartia, Claudio Salvatore; Ganzetti, Maya; Cazzola, Mario; Corso, Alessandro

doi:10.1182/blood.V128.22.5695.5695

Silvia Mangiacavalli, MD,

Silvia Mangiacavalli, MD *

1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Search for other works by this author on:

This Site

PubMed

Google Scholar

Federica Cocito, MD,

Federica Cocito, MD *

2Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, PAVIA, ITA

Search for other works by this author on:

This Site

PubMed

Google Scholar

Virginia Valeria Ferretti, PhD,

Virginia Valeria Ferretti, PhD *

3Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Search for other works by this author on:

This Site

PubMed

Google Scholar

Claudio Salvatore Cartia, MD,

Claudio Salvatore Cartia, MD *

3Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Search for other works by this author on:

This Site

PubMed

Google Scholar

Maya Ganzetti, MD,

Maya Ganzetti, MD *

4Departement of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Search for other works by this author on:

This Site

PubMed

Google Scholar

Mario Cazzola, MD,

Mario Cazzola, MD

5Departments of Hematology Oncology & Molecular Medicine, Fondazione IRCCS Policlinico San Matteo & University of Pavia, Pavia, Italy

Search for other works by this author on:

This Site

PubMed

Google Scholar

Alessandro Corso, MD

Alessandro Corso, MD *

6Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Search for other works by this author on:

This Site

PubMed

Google Scholar

Abstract

Background: Bortezomib

View large Download slide

Disclosures

Corso:Janssen-Cilag: Honoraria.

Author notes

Asterisk with author names denotes non-ASH members.

2016

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Abstract

Author notes

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Abstract

Author notes

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only